| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10 | 150 | 4,030 | $100 | $5.9M |
| J9271 | Injection, pembrolizumab, 1 mg | 11 | 20 | 360 | $8,480 | $5M |
| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 14 | 170 | 4,660 | $300 | $2.6M |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 4 | 10 | 1,030 | $1,520 | $1.9M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 42 | 480 | 4,510 | $90 | $1.8M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 5 | 10 | 890 | $1,920 | $1.7M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 45 | 660 | 460 | $90 | $1.5M |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 25 | 580 | 510 | $100 | $1.3M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 38 | 140 | 1,130 | $90 | $1.1M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 54 | 60 | 250 | $730 | $707.7K |